Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Los Angeles, California 90095


The purpose of this study is develop a new assessment tool for Attention Deficit-Hyperactivity Disorder (ADHD) and to then test its validity (i.e. ability to discriminate between individuals with ADHD and healthy controls).

Study summary:

The purpose of this study is to develop a novel approach and software for analyzing electroencephalography (EEG) data to identify biomarkers of ADHD. Then to test the ability of this assessment tool to differentiate between adults with ADHD and healthy controls by comparing the classification accuracy of the metrics from the new tool to the classification accuracy of existing behavioral tests for ADHD.


Inclusion Criteria: - Specific inclusion criteria for ADHD are: 1. meet established DSM-5 criteria for ADHD predominately inattentive or combined subtype with clinically significant levels of impairment, diagnosed by structured clinical interview, the Mini International Neuropsychiatric Interview, and corroborating information 2. Clinical Global Impression—Severity (CGI-S) score ≥ 4 for ADHD 3. no lifetime history of DSM-5 bipolar disorder, psychotic disorder, pervasive developmental disorder, obsessive-compulsive disorder, substance abuse, or substance dependence (except nicotine) as assessed wit the MINI 4. able in the opinion of the investigator to complete all required study procedures. Exclusion Criteria: - Exclusion criteria for both groups are: 1. History of diagnosis of childhood disorder other than ADHD (e.g. autism, dyslexia) 2. history of any general medical condition likely to require chronic use of medication with identified CNS effects suspected to alter cognitive performance 3. history of seizure disorder, brain tumor, other major neurological disorder or head injury resulting in loss of consciousness 4. serious oxygen deprivation 5. current psychopathology requiring ongoing treatment with antipsychotic medications, mood stabilizers, benzodiazepines, or anticonvulsants 6. current untreated psychopathology which is rated to be primary in terms of severity (greater than ADHD severity) 7. current treatment with guanfacine.



Primary Contact:

Principal Investigator
Gregory V Simpson, Ph.D.
Think Now, Inc.

Backup Contact:


Location Contact:

Los Angeles, California 90095
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.